Growing pool of patients suffering from sarcoma and increasing adoption of novel therapeutics to drive the growth of Europe soft tissue sarcoma market
According to TechSci Research report, “Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals, Oncology Center, Long Term Care Center), By Country, Forecast & Opportunities, 2025”, the market is anticipated to witness significant growth during the forecast period owing to the increase in funding by European Union for research and development to find cure and effective therapies for soft tissue sarcoma. The region is witnessing an increasing pool of patients suffering from this disease which is also acting as a major factor for the market growth. Also, growing awareness among people about soft tissue sarcoma and increasing per capita disposable income of customers are some other factors which are expected to support the growth of this market until 2025.
Additionally, European countries are witnessing a substantial increase in the approval for manufacture of generic drugs, which is serving as a major growth factor for soft tissue sarcoma market. On top of that, rise in quality patient care and patent expiry of branded drugs is encouraging more companies to enter the market. Moreover, manufacturers are engaging in extensive R&D activities to find advanced treatments such as targeted and biological therapies. Furthermore, with prevalence of around 50 different types of sarcomas, there is a growing need for better treatment in the region. Hence, all these factors are expected to drive the growth of soft tissue sarcoma market over the coming years.
However, the market might also face some restraints such as adverse side effects and high cost of therapies. Also, stringent regulatory guidelines by the government might limit the growth of soft tissue sarcoma market in Europe.
Browse XX market data Tables and XX Figures spread through XX Pages and an in-depth TOC on “Europe Soft Tissue Sarcoma Market”
https://www.techsciresearch.com/report/europe-soft-tissue-sarcoma-market/4852.html
The Europe soft tissue sarcoma market is segmented based on treatment, disease type, end user and region. Based on end user, the market is divided into hospitals, oncology center, long term care center. Among these, the oncology centers segment is anticipated to witness rapid growth during he forecast period as the region is witnessing rise in number of such centers. Moreover, the availability of such specialized centers to treat cancer-based diseases such as soft tissue sarcoma, etc., is attracting more patients to undertake the treatment, thereby fueling the market.
Based on treatment, the Europe soft tissue sarcoma market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drug and radiation therapy. Out of these, the chemotherapy segment currently dominates the market owing to its high success rate in terms of treatment. Additionally, the treatment uses a combination of various anti-cancer drugs and has high success rate compared to other cancer treatments. However, targeted therapy is expected to witness rapid growth during the forecast period owing to its superior efficacy and increasing adoption of novel therapeutics.
Major players operating in the soft tissue sarcoma market in European market include GlaxoSmithKline PLC, Eli Lilly Italia – S.P.A., Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG, Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd, MiMedx and Integra LifeSciences Services France SASU. The companies are investing in extensive R&D activities to develop more effective treatments and drugs to treat soft tissue sarcoma. Some players are also engaging in partnerships and mergers to increase their market share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4852
Customers can also request for 10% free customization on this report.
“Soft tissue sarcoma is a rare type of cancer and countries such as Germany and Italy are witnessing spike in number of patients suffering from these diseases. The recent approval of drugs like Eisai’s Halaven, which are used in chemotherapy, are boosting the market growth and the region is also witnessing entry of several new pharmaceutical manufacturers. With European Union’s focus to invest more on healthcare, the region is anticipated to emerge as a favorable market for companies dealing in medications for treating soft tissue sarcoma ,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals, Oncology Center, Long Term Care Center), By Country, Forecast & Opportunities, 2025” has evaluated the future growth potential of Europe soft tissue sarcoma market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in Europe soft tissue sarcoma market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]